Ochre Bio · Nov 2025
Ochre Bio said it completed the research phase of its GSK collaboration, delivering two human-liver datasets and moving into a multi-year co-exclusive license agreement.
RNA medicines for liver diseases
Company research
Public company, workplace, funding, and market signals
Overview
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver disease. Its platform combines large human liver datasets, AI/machine learning, in-house RNA chemistry, and ex-vivo perfused human-liver models to discover and validate targets and partner with pharma.
Primary product
RNA medicines and a human-liver discovery/validation platform for chronic liver disease
Founded
2019
Headquarters
Oxford, England, United Kingdom
Team size
50-60
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
RNA therapeutics for chronic liver disease
Offices
Oxford, England, United Kingdom (HQ)
Hayakawa Building, Edmund Halley Rd, Oxford OX4 4GB, United Kingdom
BioEscalator, Oxford Science Park, Oxford, United Kingdom
New York City, New York, United States (Alexandria Center for Life Science)
Taipei, Taiwan (tissue/research lab)
Business model
B2B pharma collaborations
data licensing
drug discovery platform partnerships
therapeutic R&D
Funding
Stage
Series A
Total raised
$39.9M
Latest round
Series A · Oct 2022
Latest amount
$30M
People & investors
Leadership
Founder and CEO
Executive Chairperson (interim)
Chief Operations Officer
Chief Business Officer
Co-founder, former CEO
Senior Director, Head of R&D
Mark Lundquist
Head of Late Stage Validation and site lead, New York City lab
Paul Foster ACMA
Director of Legal, Corporate Affairs and Company Secretary
Massoud Malang
Head of IT and Cybersecurity
Fabio Sanna
Head of Innovation
Julian Maller
Head of Computational Biology
Kelly Tompeck
Clinical Research Lead
Work & culture
Public signals describe a fast-paced, ambitious, interdisciplinary biotech with a strong human-first, data-driven culture. Ochre emphasizes speed, value-based innovation, can-do attitudes, and collaboration across Oxford, New York, and Taipei.
Work style
Onsite
Visa sponsorship
Limited
Compensation
Public postings describe compensation as competitive; one New York role was advertised at $80,000-$100,000, and at least one posting notes additional compensation for evening/weekend work.
Benefits
Covers costs of personal/professional development programs
Competitive salary on public postings
Additional compensation for evening and weekend work on some roles
Career growth in an international team
Product & market
Pricing
B2B collaboration and data-licensing agreements with milestone-based pharma partnerships; no public list pricing.
Differentiators
- —Uses live human donor livers and organ perfusion rather than animal models
- —Combines AI/machine learning with very large human liver datasets
- —Builds and uses proprietary gene perturbation and disease atlases
- —In-house RNA chemistry to shorten iteration cycles
- —Cross-site human validation across Oxford, New York, and Taipei
- —OBELiX-style human data integration for causal target discovery
Technology
Python
Nextflow
GitHub
Google Workspace
Microsoft Office
BambooHR
Smartsheet
ClickUp
The Org
AI/ML
OBELiX software
single-cell sequencing
gene perturbation atlases
human organ perfusion
primary cells
diseased tissue slices
in-house RNA chemistry
Customers
GSK
Boehringer Ingelheim
Pharma R&D partners
Competitors
Alnylam
Deep Genomics
Strand Therapeutics
Insitro
Noetik
Arctoris
Scale & contact
Estimated revenue
$10M-$20M
Latest news
Ochre Bio · Jul 2025
Ochre Bio moved its New York operations to the Alexandria Center for Life Science at 430 East 29th Street, expanding its liver-perfusion lab footprint in NYC.
Ochre Bio · Jun 2025
Ochre Bio appointed founder Quin Wills as CEO, formalizing the leadership transition after Jack O'Meara stepped down in 2024.
Business Wire · Jun 2024
GSK got access to Ochre's computational biology, cellular, and perfused human-organ platforms in a deal worth up to $37.5M for co-exclusive and non-exclusive data licenses.
Business Wire · Apr 2024
Ochre Bio announced a multi-year Boehringer Ingelheim collaboration focused on regenerative treatments for chronic liver disease, with up to $35M upfront and near-term payments and potential total value above $1B.
Jobs and careers at Ochre Bio
0 jobs at Ochre Bio
No open positions
Check back later for new openings